Dimeric 2G12 as a Potent Protection against HIV-1

被引:34
作者
Luo, Xin M. [1 ]
Lei, Margarida Y. Y. [1 ]
Feidi, Rana A. [1 ]
West, Anthony P., Jr. [1 ]
Balazs, Alejandro Benjamin [1 ]
Bjorkman, Pamela J. [1 ]
Yang, Lili [1 ]
Baltimore, David [1 ]
机构
[1] CALTECH, Div Biol, Pasadena, CA 91125 USA
关键词
IMMUNODEFICIENCY-VIRUS TYPE-1; NEUTRALIZING ANTIBODIES; MONOCLONAL-ANTIBODIES; IN-VIVO; INFECTION; 2F5; THERAPY; GP120; MICE; TRANSDUCTION;
D O I
10.1371/journal.ppat.1001225
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
We previously showed that broadly neutralizing anti-HIV-1 antibody 2G12 ( human IgG1) naturally forms dimers that are more potent than monomeric 2G12 in in vitro neutralization of various strains of HIV-1. In this study, we have investigated the protective effects of monomeric versus dimeric 2G12 against HIV-1 infection in vivo using a humanized mouse model. Our results showed that passively transferred, purified 2G12 dimer is more potent than 2G12 monomer at preventing CD4 T cell loss and suppressing the increase of viral load following HIV-1 infection of humanized mice. Using humanized mice bearing IgG "backpack'' tumors that provided 2G12 antibodies continuously, we found that a sustained dimer concentration of 5-25 mu g/ml during the course of infection provides effective protection against HIV-1. Importantly, 2G12 dimer at this concentration does not favor mutations of the HIV-1 envelope that would cause the virus to completely escape 2G12 neutralization. We have therefore identified dimeric 2G12 as a potent prophylactic reagent against HIV-1 in vivo, which could be used as part of an antibody cocktail to prevent HIV-1 infection.
引用
收藏
页数:10
相关论文
共 35 条
[1]   A phase I trial with two human monoclonal antibodies (hMAb 2F5, 2G12) against HIV-1 [J].
Armbruster, C ;
Stiegler, GM ;
Vcelar, BA ;
Jäger, W ;
Michael, NL ;
Vetter, N ;
Katinger, HWD .
AIDS, 2002, 16 (02) :227-233
[2]   Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection [J].
Baba, TW ;
Liska, V ;
Hofmann-Lehmann, R ;
Vlasak, J ;
Xu, WD ;
Ayehunie, S ;
Cavacini, LA ;
Posner, MR ;
Katinger, H ;
Stiegler, G ;
Bernacky, BJ ;
Rizvi, TA ;
Schmidt, R ;
Hill, LR ;
Keeling, ME ;
Lu, YC ;
Wright, JE ;
Chou, TC ;
Ruprecht, RM .
NATURE MEDICINE, 2000, 6 (02) :200-206
[3]   Disseminated and sustained HIV infection in CD34+ cord blood cell-transplanted Rag2-/-γc-/- mice [J].
Baenziger, Stefan ;
Tussiwand, Roxane ;
Schlaepfer, Erika ;
Mazzucchelli, Luca ;
Heikenwalder, Mathias ;
Kurrer, Michael O. ;
Behnke, Silvia ;
Frey, Joachim ;
Oxenius, Annette ;
Joller, Helen ;
Aguzzi, Adriano ;
Manz, Markus G. ;
Speck, Roberto F. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (43) :15951-15956
[4]   Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies [J].
Binley, JA ;
Wrin, T ;
Korber, B ;
Zwick, MB ;
Wang, M ;
Chappey, C ;
Stiegler, G ;
Kunert, R ;
Zolla-Pazner, S ;
Katinger, H ;
Petropoulos, CJ ;
Burton, DR .
JOURNAL OF VIROLOGY, 2004, 78 (23) :13232-13252
[5]   Changing sensitivity to broadly neutralizing antibodies b12, 2G12, 2F5, and 4E10 of primary subtype B human immunodeficiency virus type 1 variants in the natural course of infection [J].
Bunnik, Evelien M. ;
van Gils, Marit J. ;
Lobbrecht, Marilie S. D. ;
Pisas, Linaida ;
van Nuenen, Ad C. ;
Schuitemaker, Hanneke .
VIROLOGY, 2009, 390 (02) :348-355
[6]   Antibody vs. HIV in a clash of evolutionary titans [J].
Burton, DR ;
Stanfield, RL ;
Wilson, IA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (42) :14943-14948
[7]   Antibody domain exchange is an immunological solution to carbohydrate cluster recognition [J].
Calarese, DA ;
Scanlan, CN ;
Zwick, MB ;
Deechongkit, S ;
Mimura, Y ;
Kunert, R ;
Zhu, P ;
Wormald, MR ;
Stanfield, RL ;
Roux, KH ;
Kelly, JW ;
Rudd, PM ;
Dwek, RA ;
Katinger, H ;
Burton, DR ;
Wilson, IA .
SCIENCE, 2003, 300 (5628) :2065-2071
[8]   Dissection of the carbohydrate specificity of the broadly neutralizing-anti-HIV-1 antibody 2G12 [J].
Calarese, DA ;
Lee, HK ;
Huang, CY ;
Best, MD ;
Astronomo, RD ;
Stanfield, RL ;
Katinger, H ;
Burton, DR ;
Wong, CH ;
Wilson, IA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (38) :13372-13377
[9]   Gene therapy against cancer and HIV infection using the gene encoding herpes simplex virus thymidine kinase [J].
Caruso, M .
MOLECULAR MEDICINE TODAY, 1996, 2 (05) :212-217
[10]  
CHALLACOMBE SJ, 1979, IMMUNOLOGY, V36, P331